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Introduction
The phosphatidylinositol 3-kinase (PI3K) signalling pathway is involved in regulating cellular processes required for tumorigenesis, including protein synthesis, metabolism, cell survival, proliferation, apoptosis avoidance and angiogensis [1] . The class 1A PI3-kinases are a family of lipid kinases that exist as heterodimers composed of a catalytic subunit p110α and a regulatory subunit p85α. The PIK3CA gene encodes the catalytic subunit p110α. PI3K is activated by transmembrane receptor tyrosine kinases, including those of the epidermal growth factor family. In breast cancer several components of the PI3K/PTEN/AKT pathway are often dysregulated, including amplification of HER2, loss of PTEN function and mutations of the PIK3CA gene. A major mechanism for abnormal PI3K pathway activation in cancer is mutation in the PIK3CA gene, as this gene is one of the most frequently mutated oncogene in breast cancer [2] , implying that PIK3CA mutations may play an oncogenic role in breast carcinogenesis. The mutations are activating mutations, resulting in constitutive increased downstream signalling with increased pAKT [3] [4] [5] .
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As treatment in breast cancer is directed towards both subclinical (in the adjuvant setting) and clinical disease is it of crucial importance to know, whether or not the affected pathways in the primary tumors is the same as the affected pathways in the metastases.
In this study, we aimed to assess whether PIK3CA mutations and PTEN expression were concordant in paired primary and metastatic breast carcinoma. We also intended to correlate the status of PTEN and PIK3CA mutations in the metastases with pAKT to access down stream activation.
Material and Methods

Tumor samples
Formalin-fixed paraffin-embedded tumor blocks were available from 104 patients with paired samples from primary tumors and corresponding asynchronous metastatic lesions. 
Tissue Microarrays
Five-micrometer haematoxylin-eosin (HE) sections were generated from each formalin-fixed paraffin-embedded tissue block. The HE sections were reviewed by a pathologist to confirm the presence of invasive carcinoma, and areas with representative tumor tissue were sampled by two 1mm cores for Tissue microarray (TMA) preparation and DNA extraction.
Full sections
Samples with scant tumor tissue had full sections made for IHC and DNA extraction. This was the case in the majority of the metastatic samples as the biopsies were often very small. Patients with locally advanced disease at diagnosis had full sections done on the diagnostic core biopsy prior to chemotherapy. The full sections were macrodissected before mutation analysis to ensure invasive tissue in sufficient quantities.
Clinical data
Clinical data were assessed from the patients' medical files. All patients except one with primary inoperable disease underwent intended curative surgery. Ninety-one had a biopsy from their first recurrence, and 13 had a biopsy from a later recurrence with 30 biopsies originating from a locoregional recurrence and 74 from a distant recurrence. Median time to biopsy was 59 months (range Table S2 )
Immunohistochemical scoring and interpretation
Biomarker expression from immunohistochemistry assays was scored by two pathologists. ER, PTEN and pAKT staining were scored semiquantitatively using the histo-score (H-score) based on Tumors were considered negative for ER if weak immunostaining was observed in less than 1% of tumor nuclei (H-score<1) [24] . For the purposes examining the relationship between proliferation index and mutation status a cut off for Ki67 of 20 % was chosen (≤20% corresponding to a low Ki67 proliferation index), as this cut point seems to correlate with prognosis [25] and is in the range of what has been found and validated in several studies [25] [26] [27] [28] [29] [30] . PTEN staining was located mainly in the cytoplasm. Since cut off levels for reduced PTEN expression by using immunohistochemical methods are not standardized, the H-score was applied. The lower quartile corresponding to an Hscore of ≤ 10 was used as the cut off point to designate PTEN loss. Previous reports on loss of PTEN expression are in the range of 22-43 % using IHC staining [7, 21-23, 31, 32] . Phospho-AKT demonstrated predominantly cytoplasmic staining, although nuclear staining was apparent. The cytoplasmic score was taken as a more direct indicator of pathway activation and used for analyses.
The interpretation of the HER2 staining was made according to standardised guidelines for HER2
IHC interpretation [33] . Tumors were considered positive for HER2 if immunostaining was scored as 3+, or had an amplification ratio for CISH of 2.2 or more being the cut point that was used to segregate immunohistochemical equivocal tumors (scored as 2+). Logistic regression was used to test for associations with PIK3CA and the clinicopathologic variables. For the univariate analysis, time to recurrence (TTR) curves were generated by the Kaplan-Meier method, and differences between recurrence curves were assessed for significance by the log-rank test. To evaluate the independent prognostic value of PIK3CA status a multivariate analysis was carried out by multiple regression. All patients had an event and there was no censoring. TTR was defined as the time interval from surgery to date of biopsy from first relapse or date of first recurrence from the medical files in the 13 patients not having a biopsy from their first recurrence. In the correlation analyses of "PI3K pathway activity" and pAKT H-score, the nonparametric Wilcoxon Mann-Whitney test was used. All tests were two-tailed and p≤ 0.05 was considered significant. All statistical analyses were performed using STATA software version 11.
Statistical analysis
Research.
on were available for 100 patients (Table 1 and SNaPshot raw data, Table S3 , supplemental). In all 3
analyses (either exon or in combination), a gain of mutations in metastases was detected (exon 9, p=0.09; exon 20, p= 0.3). In the combined analysis, 21 patients changed genotype from wildtype to mutant (p=0.08), compared to 11 patients who lost mutations in the metastases.
A subset of the samples (randomly selected) were also analysed by DxS to validate the SNaPshot results by another method (Table 2 ). An agreement of 89 % (34/38) between the two detection methods was obtained.
Laser Capture microdissection (LCM) heterogeneity substudy
Research. In a small subset of primary tumors with mutational analyses from two tissue blocks from the same primary tumor, discrepant results lead us to look further into heterogeneity of PIK3CA mutations. In 10 primary breast cancer samples, from five patients with two discrepant primary samples, full sections followed by LCM from four different invasive areas (Figure 1and Table S4, supplemental) showed heterogeneity. In 4/10 discordance was observed between LCM and core results, with the core analysis in two samples detecting a mutation that was not detected by LCM, suggesting that a mutated subclone was located deeper in the core than the section dissected by laser capture. In one sample LCM detected a mutation that was not present by the core analysis and in the final LCM and core analysis each detected a different mutation.
Correlations with clinicopathological variables
No correlations were found between PIK3CA mutations in the primary tumors and clinicopathological parameters (Table 3) . By logistic regression analysis, there were no associations between PIK3CA mutations as dependent variable and the clinicopathological variables including nodal status, tumor size, ER, HER2, PTEN and histological type.
PIK3CA mutations and outcome
Log-rank analysis revealed that PIK3CA mutations in primary tumors (combined exon 9 and/or exon 20) were associated significantly with a longer TTR than in wildtype tumors (log-rank, p=0.03; Figure 2 ). This finding seemed to be driven more strongly by exon 9 mutations (p=0.01), as exon 20 mutations considered alone were not significantly associated with a longer TTR (p=0.07). profiles [34] [35] [36] [37] . PI3KCA mutations may be acquired during tumor progression, suggesting an increase in the activation of the PI3K pathway. Somatic mutations identified in cancers are either "drivers" or "passengers" [38] . The high frequency of PIK3CA mutations at recurrence suggests that they are driver mutations as they are biological positively selected for during tumorigenesis.
PIK3CA mutation detection methodology
PIK3CA mutations were detected by primer extension methodology with the SNaPshot assay. It is a rapid and inexpensive method, which combines multiplex PCR amplification with a multiplex primer extension assay enabling detection of all four mutations in one reaction. The method was evaluated by Hurst et al and 100 % concordant results were obtained with existing PCR-based screening methodology and no false positive results were obtained [39] . Primer extension SNaPshot assays have been developed for several genes with common mutations, e.g. BRCA1/2 [40] . It has a high analytical sensitivity as it detects mutant DNA composing 5-10 % of the total DNA present [39] . False negative results can occur due to sparse amount of tumor tissue below the detection limit. Incorrectly detected genotypes are rare (< 1 %) with this method which produces rarely (< 2 %) different genotypes in separate runs [41] . The method has numerous advantages; it is fast, sensitive -tolerating a mix of normal and small quantities of tumor tissue, and can be assessed on routine paraffin sections evading the need for frozen tumor specimens and microdissection.
Several methods for point mutation genotyping exist; though no methods have become a "golden standard". A subset of samples were analysed by both DxS and SNaPshot methods and the results were largely concordant, the SNaPshot method detecting a few more mutations than the DxS.
Importantly, in line with SNaPshot data the DxS data confirmed changed mutation status between
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Additionally the DxS results also indicate intratumoral heterogeneity.
We report high frequencies of mutations in primary breast carcinomas and metastases, and the primer extension method is likely to have superior detection rates compared to conventional sequencing with its lower sensitivity[42], because it tolerates higher levels of normal DNA contamination.
Mutational events in the tumor pathogenesis
It has been implied that PIK3CA mutations arise late in tumorigenesis as a stepwise accumulation of genetic defects resulting in progression from precursor lesions to invasive carcinoma [14, 43] . In contrast, mutations have been reported to occur in preinvasive lesions in the breast [15, 16] . Our LCM substudy indicated that primary tumors exhibit prominent microheterogeneity in PIK3CA mutation. Intratumoral genotypic and phenotypic heterogeneity in primary breast is well known, reflecting subclonal diversity [44] [45] [46] .
Our data show that overall the frequency of PIK3CA mutations in the metastases tended to increase, as more patients gained mutations. This might be due to heterogeneity in the primary tumors with small undetectable mutated subclones, which our LCM substudy supported. These subclones may in some patients grow up during tumor progression due to a selective advantage. Also while PIK3CA mutation might, for example provide for increased survival it might actually slow the rate of metastasis by reducing invasive signalling [47] . A PIK3CA mutational acquisition during tumorigenesis is also a possibility, as neoplastic progression in many tumor types involves the acquisition of molecular defect in various signalling pathways. At the same time, we observed a number of cases where a mutant primary was followed by a wild type metastasis; it is possible that a selective advantage offered by PIK3CA mutation may be substituted for by other wildtype subclones containing other aberrations inducing a more aggressive potential hence resulting in
PTEN and PI3K pathway activation
The frequency of PTEN deficiency dropped from 26% in the primary to 20% in the metastases. As metastatic samples tend to be smaller and better fixed this may reflect better epitope preservation. In any event, in contrast to PIK3CA, it does not appear that the frequency of PTEN loss increases in metastases. Pathway activation assessment in archival samples is challenging due to the strong dependence of phosphoepitope preservation on fixation. Thus, minor differences in fixation may superimpose a great deal of noise on the assay. Nonetheless, as this sample series showed relatively high levels of pAKT overall relative to other archival sets examined with the same protocol (Gardner unpublished), some speculations from the data are warranted. There was a modest association between PIK3CA mutation or PTEN loss and pAKT expression in the metastatic samples, consistent with Ellis et al [47] and prior literature reporting correlation with PIK3CA mutations/PTEN loss and activated pAKT, but this did not reach statistical significance in our study. High pAKT in general has been associated with worse outcome in breast cancer, which would thus appear to be inconsistent with the improvement in outcome associated with PIK3CA mutation. However, alterations in other pathways may be responsible for the activation of pAKT, including HER2 amplification and PTEN loss, which themselves impart a poor prognosis in breast cancer.
Targeting PI3K
Numerous inhibitors targeting the PI3K-AKT pathway for the treatment of cancer is in clinical development or in early clinical trials. These include dual PI3K-mTOR inhibitors, PI3K inhibitors, AKT inhibitors and mTOR inhibitors [49, 50] . These inhibitors might also be effective in reversing resistance to therapies. The most effective type of therapeutic used to inhibit this pathway is likely to depend on the particular mechanism of PI3K-AKT activation. Tailored amplified breast cancer, and anti EGFR therapy confined to KRAS wt colon cancer. PIK3CA mutation is predictive of response to PIK3CA inhibitors ex vivo, and may be predictive in the clinic.
Our results emphasize the attractiveness of PIK3CA inhibitory therapy in breast cancer, with the high frequency of mutation in the primaries and even higher 53 % frequency in the metastases.
Elucidating the prognostic and predictive significance of these mutations is warranted as PI3K
inhibitors become available, making clinicians able to choose and optimize appropriate tailored therapy for patients with recurrent breast cancer, and hence hopefully improve prognosis.
Importantly, our findings demonstrate that when such inhibitors are to be used in the metastatic setting, the presence of mutation should be assessed in the target lesion.
In conclusion, our findings indicate that PIK3CA mutations occur at high frequency in primary and metastatic breast cancer. Genetic as well as protein expression changes in the PI3K-AKT pathway occur at recurrence. We report a high occurrence of discrepancy in PIK3CA mutations between primary tumors and metastases, with a trend towards gain of mutations in metastatic breast cancer, and speculate that PIK3CA mutational status can be acquired during disease progression. Whether this is due to heterogeneity related clonal selection or late stage acquisition of mutations during the process of metastasis is unknown, but may have an impact when using PI3K targeted therapy in the metastatic setting and if confirmed, emphasizes the necessity of determining the PIK3CA mutational status in the metastatic disease. 
